Nov 9 (Reuters) - An AstraZeneca (AZN.L), opens new tab executive said he felt encouraged by "incredibly promising" COVID-19 vaccine trial data unveiled by Pfizer and its German partner BioNTech, ...

Pfizer ended its six-month effort to buy AstraZeneca Monday following the London-based company's May 19 rejection of its last bid of 55 pounds a share in cash and stock. While British takeover law ...

LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to ...

The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular ...

Amid looming 100% tariffs on imported drugs by the Trump administration, global pharmaceutical companies are significantly ...

The firm expects Phase III data for its investigational selective estrogen receptor degrader camizestrant and its CLDN18.2 ADC sonesitatug vedotin this year.